Bladder preservation for MIBC after perioperative EV + pembrolizumab complete response
If the ADC-immunotherapy combination erases the tumour in more than half of patients before surgery, some may not need their bladder removed at all.
pCR 57% in EV-303 and high pCR in EV-304 raise the question that dostarlimab answered in dMMR rectal cancer: can complete responders skip surgery? Trials (e.g., SunRISe-4 arms, MODERN, and investigator-led bladder-sparing studies) are beginning to test cystectomy omission with ctDNA and MRI-guided surveillance.
Pages like this
not linked directly; found by shared links- PairingEnfortumab vedotin + pembrolizumab across the bladder cancer continuum
Shares EV-304 / KEYNOTE-B15, EV-303 / KEYNOTE-905, Enfortumab vedotin, Bladder & urothelial cancer.
- PersonShilpa Gupta
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- PersonJae Lyun Lee
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- TrialEV-302 / KEYNOTE-A39
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- IdeaA national residual-disease weather service: serial blood tests for every curatively treated patient, pooled
Shares Signatera, MRD / molecular residual disease testing, Bladder & urothelial cancer.
- TargetNectin-4
Shares EV-303 / KEYNOTE-905, Enfortumab vedotin, Bladder & urothelial cancer.
- PairingctDNA MRD → adjuvant therapy decision
Shares Signatera, MRD / molecular residual disease testing, Bladder & urothelial cancer.
- TechnologyADC payload neutralisers